SecBot SecBot
8-K ·Filed May 14, 2026

BIIB

BIOGEN INC.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001193125-26-222908
8-K material event: Items 1.01, 2.01
Actionable Insight ▲ Bullish

The acquisition is immediately transformative for Biogen's near-term growth, adding ~$689M in 2025 revenue from EMPAVELI/SYFOVRE and a nephrology pipeline. The $2B debt raise increases leverage but is manageable given Biogen's scale. Monitor Q2 earnings for updated 2026 guidance and SYFOVRE sales trajectory, which directly impacts CVR probability. The CVRs are non-transferable and not listed, so no direct trading vehicle exists.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$191.26
T+0 close · May 14, 2026 · via day close
Latest settled
+8.15%
T+60 · $206.85
Vs SPY
+4.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $191.26entry
  2. T+1 · 6mo ago +0.55%α +1.78% · $192.32
  3. T+5 · 6mo ago −1.23%α −0.52% · $188.90
  4. T+20 · 5mo ago +4.60%α +5.46% · $200.05
  5. T+60 · 3mo ago +8.15%α +4.83% · $206.85

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen completed its $5.3B acquisition of Apellis Pharmaceuticals on May 14, 2026, adding commercial-stage products EMPAVELI and SYFOVRE. The deal was funded via a $2B term loan facility and cash. Apellis shareholders received $41/share plus one CVR per share, with potential milestone payments of up to $4/share tied to SYFOVRE net sales thresholds of $1.5B and $2.0B through 2031. The acquisition is expected to be accretive to Biogen's non-GAAP EPS in 2027.

Key Financial Metrics

Deal Value
$5.3B
Deal Type
acquisition

Key Facts

  • Biogen completed acquisition of Apellis Pharmaceuticals on May 14, 2026 for ~$5.3B in cash and CVRs.
  • Apellis shareholders received $41.00 per share in cash plus one contingent value right (CVR) per share.
  • CVRs entitle holders to up to $4.00 per share in milestone payments tied to SYFOVRE net sales thresholds of $1.5B and $2.0B through 2031.
  • Biogen borrowed the full $2B under a new term loan facility ($1B 364-day Tranche A, $1B 2-year Tranche B) to fund the acquisition.
  • The acquisition adds EMPAVELI and SYFOVRE, which recorded $689M in combined net product revenue in 2025.
  • Biogen expects the deal to be accretive to non-GAAP diluted EPS in 2027 and to materially increase non-GAAP EPS CAGR through the end of the decade.
  • Approximately 105.7M shares (82.4% of outstanding) were validly tendered in the offer.
  • Biogen estimates it would need ~$582M to pay the maximum aggregate CVR milestone amounts if all thresholds are achieved.

Financial Impact

Total acquisition consideration ~$5.3B in cash plus up to ~$582M in potential CVR milestone payments. Funded via $2B term loan and cash on hand.

revenueepsdebtdilution

Risk Factors

  • SYFOVRE faces competition from other GA therapies (e.g., Avacincaptad pegol) which could pressure market share and net sales.
  • CVR milestones are contingent on SYFOVRE achieving $1.5B and $2.0B annual net sales by 2031, no guarantee of achievement.
  • Integration risk: combining Apellis' commercial and R&D operations with Biogen's existing infrastructure.
  • Increased leverage from $2B term loan; financial covenant requires max consolidated leverage ratio of 3.75x (4.25x temporarily post-acquisition).

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
56% bullish (43 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-222908
Document: d109852dex101.htm0001193125-26-222908
Document: d109852dex991.htm0001193125-26-222908
Document: d109852d8k.htm0001193125-26-222908
Document: 0001193125-26-222908-index-headers.html0001193125-26-222908
Document: 0001193125-26-222908-index.html0001193125-26-222908
Document: 0001193125-26-222908.txt0001193125-26-222908

Track record

34 reports on BIIB

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026